R.B. Berryman

572 total citations
16 papers, 237 citations indexed

About

R.B. Berryman is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, R.B. Berryman has authored 16 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in R.B. Berryman's work include Acute Myeloid Leukemia Research (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). R.B. Berryman is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). R.B. Berryman collaborates with scholars based in United States, Germany and United Kingdom. R.B. Berryman's co-authors include Scott E. Smith, Ranjana H. Advani, Laurie E. Grove, Jasmine Zain, Ajay K. Gopal, Owen A. O’Connor, Jeffrey Matous, Achim Rothe, Radhakrishnan Ramchandren and Robert Chen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

R.B. Berryman

15 papers receiving 231 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.B. Berryman United States 8 111 104 92 50 40 16 237
Yazeed Sawalha United States 8 99 0.9× 97 0.9× 26 0.3× 18 0.4× 53 1.3× 43 169
Masahiro Sekimizu Japan 8 131 1.2× 89 0.9× 42 0.5× 44 0.9× 23 0.6× 42 249
Pat Stiff United States 7 73 0.7× 89 0.9× 90 1.0× 38 0.8× 68 1.7× 13 208
Andrea Meinhardt Germany 4 219 2.0× 155 1.5× 22 0.2× 93 1.9× 69 1.7× 7 282
Catherine Hildyard United Kingdom 7 144 1.3× 41 0.4× 67 0.7× 66 1.3× 102 2.5× 12 223
Joel Wight Australia 8 104 0.9× 58 0.6× 24 0.3× 43 0.9× 43 1.1× 22 157
Efthymios Karmiris Greece 9 122 1.1× 34 0.3× 20 0.2× 36 0.7× 63 1.6× 43 276
Christian Kraus United States 5 310 2.8× 87 0.8× 35 0.4× 125 2.5× 44 1.1× 7 374
Michela Ansuinelli Italy 6 89 0.8× 63 0.6× 27 0.3× 42 0.8× 24 0.6× 13 140
Ana Jiménez Ubieto Spain 9 78 0.7× 95 0.9× 68 0.7× 7 0.1× 50 1.3× 42 212

Countries citing papers authored by R.B. Berryman

Since Specialization
Citations

This map shows the geographic impact of R.B. Berryman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.B. Berryman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.B. Berryman more than expected).

Fields of papers citing papers by R.B. Berryman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.B. Berryman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.B. Berryman. The network helps show where R.B. Berryman may publish in the future.

Co-authorship network of co-authors of R.B. Berryman

This figure shows the co-authorship network connecting the top 25 collaborators of R.B. Berryman. A scholar is included among the top collaborators of R.B. Berryman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.B. Berryman. R.B. Berryman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Han, Tae Hyung, Ranjana H. Advani, R.B. Berryman, et al.. (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemotherapy and Pharmacology. 72(1). 241–249. 13 indexed citations
3.
Shaughnessy, Paul, Joseph P. Uberti, Steven M. Devine, et al.. (2012). Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplantation. 48(6). 777–781. 29 indexed citations
4.
Gopal, Ajay K., Radhakrishnan Ramchandren, Owen A. O’Connor, et al.. (2012). Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 120(3). 560–568. 108 indexed citations
5.
Forero‐Torres, Andres, R.B. Berryman, Ranjana H. Advani, et al.. (2011). Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),. Blood. 118(21). 3711–3711. 9 indexed citations
6.
7.
8.
Miller, Ashley M., R. Schneider, Edward Agura, et al.. (2011). Weekly Bortezomib for the Treatment of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD). Biology of Blood and Marrow Transplantation. 17(2). S343–S343. 2 indexed citations
9.
10.
Chuang, Wan‐Long, et al.. (2009). Medactionplan.com As a Tool for Patient Education and Medication Management in the Blood and Marrow Transplant Setting. Biology of Blood and Marrow Transplantation. 15(2). 34–34. 2 indexed citations
11.
Agura, E.D., R.B. Berryman, Breanna Cooper, et al.. (2007). Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Journal of Clinical Oncology. 25(18_suppl). 7064–7064. 2 indexed citations
12.
13.
14.
Saracino, Giovanna, R.B. Berryman, JW Fay, et al.. (2005). Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplantation. 35(8). 747–754. 16 indexed citations
15.
Hosking, D. J., John Kemm, Megan Knight, et al.. (1983). SCREENING FOR SUBCLINICAL OSTEOMALACIA IN THE ELDERLY: NORMAL RANGES OR PRAGMATISM?. The Lancet. 322(8362). 1290–1292. 12 indexed citations
16.
Berryman, R.B.. (1960). A Physical Model for the Experiment. Perceptual and Motor Skills. 11(1). 3–12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yazeed Sawalha Breakdown of academic impact, for papers by Masahiro Sekimizu Breakdown of academic impact, for papers by Pat Stiff Breakdown of academic impact, for papers by Andrea Meinhardt Breakdown of academic impact, for papers by Catherine Hildyard Breakdown of academic impact, for papers by Joel Wight Breakdown of academic impact, for papers by Efthymios Karmiris Breakdown of academic impact, for papers by Christian Kraus Breakdown of academic impact, for papers by Michela Ansuinelli Breakdown of academic impact, for papers by Ana Jiménez Ubieto
Rankless by CCL
2026